SG11201808192RA - Non-invasive diagnostic of non-alcoholic steatohepatitis - Google Patents

Non-invasive diagnostic of non-alcoholic steatohepatitis

Info

Publication number
SG11201808192RA
SG11201808192RA SG11201808192RA SG11201808192RA SG11201808192RA SG 11201808192R A SG11201808192R A SG 11201808192RA SG 11201808192R A SG11201808192R A SG 11201808192RA SG 11201808192R A SG11201808192R A SG 11201808192RA SG 11201808192R A SG11201808192R A SG 11201808192RA
Authority
SG
Singapore
Prior art keywords
international
lille
alcoholic steatohepatitis
rue
nash
Prior art date
Application number
SG11201808192RA
Inventor
Raphaël Darteil
Geneviève Cordonnier
John Brozek
Emilie Praca
Sudrik Fouad Ben
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of SG11201808192RA publication Critical patent/SG11201808192RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/54—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving glucose or galactose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06F—ELECTRIC DIGITAL DATA PROCESSING
    • G06F17/00—Digital computing or data processing equipment or methods, specially adapted for specific functions
    • G06F17/10—Complex mathematical operations
    • G06F17/18—Complex mathematical operations for evaluating statistical data, e.g. average values, frequency distributions, probability functions, regression analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/20—Probabilistic models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Data Mining & Analysis (AREA)
  • Public Health (AREA)
  • Pathology (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Databases & Information Systems (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Software Systems (AREA)
  • Computational Mathematics (AREA)
  • Mathematical Optimization (AREA)
  • Mathematical Analysis (AREA)
  • Pure & Applied Mathematics (AREA)
  • Emergency Medicine (AREA)
  • Mathematical Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111 HO 1111101110111100111111111001111111101111011111 International Bureau r..... .Yi j (10) International Publication Number (43) International Publication Date .......,,,i WO 2017/167934 Al 5 October 2017 (05.10.2017) IN I PO I P CT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12Q 1/68 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/EP2017/057633 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: 30 March 2017 (30.03.2017) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 16163048.8 30 March 2016 (30.03.2016) EP (84) Designated States (unless otherwise indicated, for every (71) Applicant: GENFIT [FR/FR]; 885 avenue Eugene Avinee, 59120 LOOS (FR). kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, — (72) Inventors: DARTEIL, Raphael; 72, rue d'Artois, 59000 LILLE (FR). CORDONNIER, Genevieve; 13, rue du President Pompidou, 59175 TEMPLEMARS (FR). BROZEK, John; 855 me Albert Camus-Carriere Demory, 59230 SAINT-AMAND-LES-EAUX (FR). PRACA, Em- ilie; 22 me Armand Barbes, 59000 LILLE (FR). BEN TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). SUDRIK, Fouad; 81 me de Jemmapes, 59000 LILLE Published: (FR). — with international search report (Art. 21(3)) Agent: CABINET BECKER ET ASSOCIES; 25, me Louis le Grand, 75002 PARIS (FR). (74) _ with sequence listing part of description (Rule 5.2(a)) = = = = = = = = Il 7r M t:I ' IN 11 IN 11 © N (54) Title: NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS C ) ,.. (57) : The invention relates to a novel method for the diagnosis of non-alcoholic steatohepatitis (NASH), and for classify- ing a subject as a potential receiver of a treatment for NASH.
SG11201808192RA 2016-03-30 2017-03-30 Non-invasive diagnostic of non-alcoholic steatohepatitis SG11201808192RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16163048 2016-03-30
PCT/EP2017/057633 WO2017167934A1 (en) 2016-03-30 2017-03-30 Non-invasive diagnostic of non-alcoholic steatohepatitis

Publications (1)

Publication Number Publication Date
SG11201808192RA true SG11201808192RA (en) 2018-10-30

Family

ID=55806131

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808192RA SG11201808192RA (en) 2016-03-30 2017-03-30 Non-invasive diagnostic of non-alcoholic steatohepatitis

Country Status (15)

Country Link
US (1) US20190352715A1 (en)
EP (2) EP3436600B1 (en)
JP (2) JP7418959B2 (en)
KR (1) KR102646698B1 (en)
CN (1) CN109072302B (en)
AU (2) AU2017242818B2 (en)
BR (1) BR112018069560A2 (en)
CA (1) CA3018133A1 (en)
EA (1) EA201892201A1 (en)
IL (1) IL261814A (en)
MX (1) MX2018011633A (en)
PH (1) PH12018502057A1 (en)
SG (1) SG11201808192RA (en)
WO (1) WO2017167934A1 (en)
ZA (1) ZA201807083B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7418959B2 (en) * 2016-03-30 2024-01-22 ジェンフィ Non-invasive diagnosis of non-alcoholic steatohepatitis
US10624944B2 (en) * 2017-06-19 2020-04-21 Creative Bio-Peptides Inc. Anti-inflammatory peptides for treating non-alcoholic steatohepatitis (NASH)
US20200340060A1 (en) * 2017-11-13 2020-10-29 Gilead Sciences, Inc. Compositions and methods for identifying and treating liver diseases and monitoring treatment outcomes
JP7239139B2 (en) * 2018-08-03 2023-03-14 国立大学法人金沢大学 Methods for diagnosing liver cirrhosis, methods for diagnosing complications of nonalcoholic steatohepatitis and hepatocellular carcinoma, and methods for diagnosing complications of nonalcoholic steatohepatitis and esophagogastric varices
US20210244744A1 (en) * 2018-08-30 2021-08-12 Terns Pharmaceuticals, Inc. Treating liver disorders
MX2021010475A (en) 2019-03-13 2021-10-01 Genfit Diagnosis of non-alcoholic steatohepatitis.
MX2021012610A (en) * 2019-04-16 2021-11-12 Genfit Compositions and methods for the stabilization of micro-rna.
WO2021149719A1 (en) * 2020-01-24 2021-07-29 アルプスアルパイン株式会社 Method of using mirna expression level as indicator of cancer
EP4237858A1 (en) 2020-10-30 2023-09-06 Genfit Methods of diagnostic of liver fibrosis
RU2760092C1 (en) * 2021-03-29 2021-11-22 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью Method for the diagnosis of non-alcoholic fatty liver disease in men of the european population during screening examinations
CN113160983A (en) * 2021-04-09 2021-07-23 南京医科大学附属逸夫医院 Metabolism-related fatty liver disease clinical prediction model
US20220340962A1 (en) 2021-04-22 2022-10-27 Genfit Quantitative detection of micro-rnas
KR102521638B1 (en) * 2021-05-21 2023-04-14 브렉소젠 주식회사 A marker for diagnosis of nonalcoholic fatty liver disease
CA3213732A1 (en) 2021-06-16 2022-12-22 Yacine HAJJI Method for nash risk assessment in patients having a metabolic disorder
WO2023194593A1 (en) * 2022-04-08 2023-10-12 Genfit Improved diagnosis of nonalcoholic steatohepatitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2841784B1 (en) * 2002-07-08 2007-03-02 COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2EN-1-ONE DERIVATIVES, PREPARATION AND USES
US7856319B2 (en) 2005-02-03 2010-12-21 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of alcoholic steato-hepatitis using biochemical markers
WO2012012051A2 (en) * 2010-07-20 2012-01-26 Trustees Of Dartmouth College Method for multicolor codetection of microrna and proteins
WO2012105590A1 (en) * 2011-02-01 2012-08-09 アステラス製薬株式会社 Determination marker for non-alcoholic steatohepatitis, and method for diagnosing non-alcoholic steatohepatitis using the marker as measure
US20120264824A1 (en) * 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014049131A1 (en) 2012-09-28 2014-04-03 Université d'Angers Accurate blood test for the non-invasive diagnosis of non-alcoholic steatohepatitis
WO2015192854A2 (en) * 2014-06-16 2015-12-23 Aarhus Universitet Methods and tools for predicting steatohepatitis
CN104293908A (en) * 2014-06-18 2015-01-21 镇江市第三人民医院 Serum miRNA maker assemblage for detecting nonalcoholic fatty liver, and its application
CN108138232B (en) * 2015-09-14 2023-07-18 基恩菲特公司 Methods for diagnosing and assessing non-alcoholic steatohepatitis
JP7418959B2 (en) * 2016-03-30 2024-01-22 ジェンフィ Non-invasive diagnosis of non-alcoholic steatohepatitis

Also Published As

Publication number Publication date
CA3018133A1 (en) 2017-10-05
AU2023201802A1 (en) 2023-04-27
JP7418959B2 (en) 2024-01-22
IL261814A (en) 2018-10-31
JP2019511225A (en) 2019-04-25
KR102646698B1 (en) 2024-03-12
JP2022078250A (en) 2022-05-24
CN109072302A (en) 2018-12-21
EP3985126A1 (en) 2022-04-20
EP3436600B1 (en) 2024-01-17
MX2018011633A (en) 2019-01-10
EP3436600A1 (en) 2019-02-06
WO2017167934A1 (en) 2017-10-05
AU2017242818B2 (en) 2023-04-27
CN109072302B (en) 2024-01-16
EA201892201A1 (en) 2019-03-29
KR20180132092A (en) 2018-12-11
AU2017242818A1 (en) 2018-10-04
PH12018502057A1 (en) 2019-06-24
US20190352715A1 (en) 2019-11-21
ZA201807083B (en) 2019-06-26
EP3436600C0 (en) 2024-01-17
BR112018069560A2 (en) 2019-01-29

Similar Documents

Publication Publication Date Title
SG11201808192RA (en) Non-invasive diagnostic of non-alcoholic steatohepatitis
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804934PA (en) Novel Compounds
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201907673YA (en) Pharmaceutical compositions for combination therapy
SG11201909960UA (en) Methods for improving memory and cognition and for treating memory and cognitive disorders
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201804263PA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201808106YA (en) Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation
SG11201806868TA (en) Compositions and methods for protecting against airborne pathogens and irritants
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201906987RA (en) Combination of a ppar agonist with a fxr agonist
SG11201900238UA (en) Compounds and methods for modulation of smn2
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201805387RA (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
SG11201810974QA (en) Methods and compositions for prostate cancer diagnosis and treatment
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201808540SA (en) Methods of treatment for cholestatic and fibrotic diseases
SG11201805263TA (en) Compositions and methods for detecting and treating esophageal cancer
SG11201901689YA (en) Compounds for treating diseases associated with a mitochondrial dysfonction